Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Clinical trial NCT05985954 · RECRUITING
Trial details
- NCT number
- NCT05985954
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-18
- Primary completion
- 2028-03-28
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.